Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 236 of 6351
-
Can AI coach autistic individuals in social skills?
Symptom relief Recruiting nowThe purpose of this study is to identify whether researched and commonly used face-to-face interventions can be effectively implemented through artificial intelligence (AI) using an application on the phone or computer. The investigators plan to recruit individuals diagnosed with…
Sponsor: Stanford University • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can a pill reverse severe baldness? major trial underway
Disease control Recruiting nowAlopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upa…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Head-to-Head: which migraine pill is kinder to patients?
Disease control CompletedA migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The main goal of the study is to evaluate the tolerability (how patients handle the study treatment) and …
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a daily pill keep brain lymphoma at bay after remission?
Disease control Recruiting nowA double-blind, randomized phase II comparative trial will evaluate the superiority of the investigational treatment (tirabrutinib maintenance therapy) over standard care (observation with placebo) in terms of progression-free survival in patients with newly diagnosed primary cen…
Phase 2 • Sponsor: Kyorin University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a weekly infusion reach the brain to fight a rare childhood disease?
Disease control OngoingA Phase I/ II, open-label, randomized, 2-arm study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIA patients.
Phase 1/2 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Boosting CAR t cells: could a pill make lymphoma therapy more effective?
Disease control OngoingThis is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothe…
Phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
A biologic shot may rewire nasal polyps for years of relief
Disease control OngoingThe investigators propose a real-world study to assess the mechanism of action of long-lasting response to mepolizumab in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and identify clinically useful predictors of response. Mepolizumab is a monoclonal antibod…
Phase 4 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could a Slow-Drip drug tame multiple myeloma with fewer side effects?
Disease control Recruiting nowPrimary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI). Secondary Objectives * • To establish the pharmacokinetic (PK) pro…
Phase 1/2 • Sponsor: Starton Therapeutics, Inc • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Heart shield: diabetes drug may prevent Chemo-Induced cardiac damage
Prevention OngoingEMPACT (EMPAgliflozin in prevention of chemotherapy-related CardioToxicity) study is a randomized, multi-center, placebo-controlled, double-blind trial to evaluate efficacy of empagliflozin in prevention of left ventricular (LV) dysfunction in patients receiving high cumulative d…
Phase 3 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New pill takes aim at tough lung cancer mutations
Disease control Recruiting nowStudy STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 inserti…
Phase 1/2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a targeted antibody-drug combo tackle rare bladder cancers?
Disease control Recruiting nowThis phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of less common types of bladder cancer) that have spread to nearby tissue or lymph nodes (locally advanced) or that has spread…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New immune therapies aim to tackle High-Risk myeloma early
Disease control OngoingThe goal of this Phase 2, open-label, multicenter, non-randomized pilot study is to evaluate the efficacy (in terms of MRD negative CR rate after Intensification therapy) and safety of Tec-Dara (Teclistamab+Daratumumab) and Tal-Dara (Talquetamab+Daratumumab) in de novo high-risk …
Phase 2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Custom-Made vaccine takes aim at rare childhood cancers
Vaccine Recruiting nowThe PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and normal tissue as well as RNA sequencing of the tumor. T…
Phase 1/2 • Sponsor: University Hospital Tuebingen • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
-
Rewiring the mind after trauma: a new therapy aims to change how we process painful events
Disease control Recruiting nowThe R33 will be a randomized controlled trial to replicate changes in the targets (unproductive processing, avoidance, reward deficits) from the R61 phase in a larger sample of 135 participants who have experienced a destabilizing life event involving profound loss or threat, rep…
Sponsor: Case Western Reserve University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
The longevity gene hunt: can families reveal the secret to a long, healthy life?
Knowledge-focused OngoingThe demographic life expectancy enhancement of the past 150 years imposes an urgent challenge in Western and economically growing societies to stimulate the healthy lifespan that is lagging behind. Families surviving into exceptionally high ages (longevity) in good physical and m…
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
New drug aims to stop liver decline in PBC patients with cirrhosis
Disease control Recruiting nowTo Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Phase 3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a new drug save Babies' brains after oxygen loss?
Disease control Recruiting nowSovateltide (PMZ-1620; IRL-1620) is targeted to be used as a "Treatment for hypoxic-ischemic encephalopathy in neonates," which is a life-threatening condition. Sovateltide augments neuronal progenitor cell differentiation and better mitochondrial morphology and biogenesis to act…
Phase 2 • Sponsor: Pharmazz, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for lymphoma patients: drug cocktail aims to control relapsed disease
Disease control Recruiting nowThis is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated w…
Phase 3 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can brain games and gentle currents lift long COVID brain fog?
Symptom relief CompletedThis platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a p…
Sponsor: Duke University • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Could a gentler chemo cocktail beat breast cancer with fewer side effects?
Disease control OngoingThis phase II study evaluates the efficacy and safety of a de-escalated neoadjuvant chemotherapy regimen in patients with early-stage HER2-positive breast cancer. The experimental regimen consists of 12 weekly cycles of paclitaxel combined with trastuzumab and pertuzumab (THP), w…
Phase 2 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC